Healthcare / Drug Manufacturers - Specialty & GenericJohannesburg
$3.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
0.2x
↓EV/EBITDA
26.2x
↑ROE
80.8%
↑Gross Margin
58.9%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+61.6%
FCF CAGR
—
FCF margin
-8.2%
FCF / Net income
-0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $199.4M · net income $117.9M · FCF $-16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $199.4M | $199.4M | $48.5M | $49.5M | $29.3M |
| Net Income | $117.9M | $117.9M | $-25.8M | $-86.9M | $-22.8M |
| EBITDA | $128.8M | $128.8M | $-18.0M | $-68.2M | $2.2M |
| EPS | 0.10 | 0.10 | -0.04 | -0.14 | -0.06 |
| Gross Margin | 58.9% | 58.9% | 61.5% | 42.8% | 43.0% |
| Operating Margin | 30.1% | 30.1% | -56.0% | -74.7% | -168.1% |
| Net Margin | 59.1% | 59.1% | -53.2% | -175.4% | -77.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | -0.56 | 31.86 | 0.15 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.3M | $-16.3M | $2.9M | $-7.3M | $-6.9M |
| Returns | |||||
| ROE | 80.8% | 80.8% | 108.4% | -20839.6% | -24.9% |
| Valuation | |||||
| P/E | 0.23 | 0.23 | — | — | — |
| EV/EBITDA | 26.21 | 26.21 | — | — | 42.21 |
| P/B | 22.89 | 22.89 | — | 117.03 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | 310.8% | 310.8% | -2.0% | 69.2% | — |
| EPS Growth | 362.2% | 362.2% | 72.1% | -150.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.7%
EPS terminal req.
$0.27
Spread vs growth
325.5%
5Y implied EPS CAGR
25.3%
EPS terminal req.
$0.32
Spread vs growth
336.9%
10Y implied EPS CAGR
17.4%
EPS terminal req.
$0.52
Spread vs growth
344.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → 0.10
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.